Ostentus Therapeutics is focused on developing effective and safe plant-derived anti-cancer drugs, with a particular emphasis on their lead compound, OST-01. The company has conducted extensive pharmacological characterization of OST-01, particularly in models of acute myeloid leukemia (AML), utilizing patient-derived xenograft (PDX) models that closely mimic human disease. Their research has included in vitro studies on cell proliferation, differentiation, and apoptosis, supported by RNA sequencing and gene enrichment analyses to uncover the cellular pathways influenced by OST-01. Additionally, they have employed proteomics and metabolomics techniques to assess how OST-01 and its derivatives affect protein synthesis and metabolism in cancer cells.

The efficacy of OST-01 has been evaluated through dose-searching studies in both AML and breast cancer models, demonstrating its potential therapeutic benefits. Preliminary toxicology assessments have also been conducted, examining the effects of OST-01 on major organs and tissues in treated mice, with oversight from a licensed veterinary pathologist. Ongoing research includes mass-spectrometry studies aimed at identifying the active components of OST-01 and validation studies to further explore the individual components of OST-01 and its derivatives. This comprehensive approach underscores Ostentus Therapeutics' commitment to advancing plant-derived therapies for cancer treatment.

United States

Ostentus Therapeutics is a biotechnology company that studies novel natural compounds in the treatment of cancer. They have entered into Sponsored Research Agreements with City of Hope to continue studies of novel OST natural products for the treatment of leukemia and other cancers. The company has also been involved in research related to in vivo antileukemic activity of OST-01 in acute myeloid leukemia.

Ostentus Therapeutics

Company Details